Publication | Closed Access

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

Radiation MedicineUrologyRadiation TherapyMedicineRadium-223 ChlorideOverall Survival BenefitCastration-resistant Prostate CancerCancer TreatmentProstatic DiseaseOncologyRadiation Oncology